Neuro-regenerative personalized medicine is one of the most promising therapies, which needs dedicated uniform standards and regulations.
Neuroplast has raised $11.3M in total funding. The most recent round was Series B. The last funding was announced in November 2021.
Neuroplast's investors include Brightlands Venture Partners, Lumana Invest, NV Industriebank LIOF.
Neuroplast is headquartered in Geleen, The Netherlands.
Neuro-regenerative personalized medicine is one of the most promising therapies, which needs dedicated uniform standards and regulations.
Neuroplast is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Neuroplast — Funding & Investors." VCBacked, November 17, 2021, https://www.vcbacked.co/company/neuroplast. Accessed August 13, 2026.
VCBacked. (2021). Neuroplast — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/neuroplast
{{cite web |title=Neuroplast — Funding & Investors |url=https://www.vcbacked.co/company/neuroplast |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated